T Cell‐Signaling‐Responsive Conjugate of Antibody with siRNA to Overcome Acquired Resistance to anti‐PD‐1 Immunotherapy
- 5 October 2021
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 5 (1), 2100161
- https://doi.org/10.1002/adtp.202100161
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20202004)
- National Natural Science Foundation of China (21877058, 22077063, 21977043, 91753116)
- Fundamental Research Funds for the Central Universities (020514380226)
This publication has 36 references indexed in Scilit:
- Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic MelanomaClinical Cancer Research, 2018
- Targeting immunosuppressive adenosine in cancerNature Reviews Cancer, 2017
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityNature, 2017
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activityProceedings of the National Academy of Sciences of the United States of America, 2017
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancerOncoImmunology, 2016
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNature Communications, 2016
- Acquired resistance to immunotherapy and future challengesNature Reviews Cancer, 2016
- Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomesEuropean Journal of Cell Biology, 2000